NCT07321886

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,980 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Eloralintide	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2026-02-06
• Primary completion: 2028-03-01
• Completion: 2030-07-01
• First posted: 2026-01-07
• Last updated: 2026-04-17

Locations

173 sites across 15 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, China, Germany, India, Japan, Poland, Puerto Rico, South Korea, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study